Press Release: Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance

Dow Jones11-06
ATLANTA--(BUSINESS WIRE)--November 05, 2026-- 

Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the third quarter ended September 30, 2026. The Company also raised its full-year guidance.

Third Quarter Financial Results

   --  Residents served ended the quarter at approximately 218,000, up 7% 
      year-over-year. 
 
   --  Reported Revenue of $371.1 million, inclusive of pricing decreases as a 
      result of the IRA, down 2% year-over-year. 
 
   --  Net Income of $19.1 million, compared to $9.6 million in the prior-year 
      period. 
 
   --  Adjusted EBITDA of $33.9 million, up 24% year-over-year. 
 
   --  Diluted EPS of $0.29 for the quarter, with Adjusted EPS of $0.33.1 
 
   --  Cash and cash equivalents totaled $119.7 million at quarter-end, with 
      no long-term debt outstanding under our credit facility. 

CEO Commentary

"We are very pleased with our third-quarter performance, highlighted by strong resident and prescription growth. Absent the price reductions from the IRA, revenues would have been up high single digits compared to the third quarter of 2025, mostly driven by organic growth," said Fred Burke, President and Chief Executive Officer. "Our margin improvement demonstrates the scalability of Guardian's operating model, as well as the progress we are making in driving profitability and leverage across our growing resident base. This performance, together with our positive outlook for the remainder of the year, supports our decision to raise full-year guidance."

Burke added, "With favorable industry fundamentals, a substantial runway for growth, and a liquid balance sheet, we believe Guardian is well positioned to generate durable growth and attractive long-term returns for shareholders."

FY 2026 Outlook -- Updating Guidance

The guidance below excludes any future acquisitions.

 
                       Updated Guidance              Previous Guidance 
---------------  ----------------------------  ----------------------------- 
Revenue          $1.44 billion -$1.46 billion  $1.43 billion - $1.45 billion 
---------------  ----------------------------  ----------------------------- 
Adjusted EBITDA  $136 million - $138 million    $129 million - $131 million 
---------------  ----------------------------  ----------------------------- 
 

M&A and Greenfields

Guardian continued to advance its growth strategy during the quarter in both new and adjacent markets.

In July, Guardian completed the acquisition of Wellness Concepts, a long-term care pharmacy serving Virginia's Shenandoah Valley region. This pharmacy has an established reputation for high-quality service and care, and its integration is progressing as planned.

Guardian also completed the acquisition of certain assets of Nautilus, a pharmacy services provider that previously served assisted living communities across 14 states through a centralized mail-order model. Guardian successfully transitioned the acquired resident base to 18 existing pharmacies within Guardian's network, providing these communities access to Guardian's locally managed, high-touch pharmacy services. The transaction offers an attractive opportunity to leverage existing infrastructure and operating capacity to generate incremental earnings with limited additional investment.

Subsequent to quarter-end, we added a small pharmacy in Sioux City, Iowa. Collectively, with our existing pharmacy in that area, it gives us a more significant presence in the Northwest part of the state.

Earlier this week, Guardian completed the acquisition of Van's Institutional Pharmacy, a well-established long-term care pharmacy serving communities across western Tennessee and Kentucky. With a history spanning more than 50 years, Van's brings a strong reputation for quality care and service. The acquisition increases Guardian's Tennessee footprint to five pharmacy locations.

Guardian also made progress on its greenfield development initiatives. Its previously announced pharmacy in Lexington, Kentucky is now operational. We are also advancing plans to expand our presence in Texas and Alabama, with new locations in Houston and Huntsville, respectively. Each location will represent our second pharmacy in those states.

To support its expanding pharmacy network, Guardian continues to strengthen regional leadership and operational coordination, with a focus on sharing best practices, enhancing customer service, and capturing efficiencies while preserving the locally managed operating model that distinguishes the Company.

 
____________________________ 
(1) Diluted EPS and Adjusted EPS include dilutive shares related to restricted 
stock units. See reconciliation of Adjusted EPS to Diluted EPS, the most 
directly comparable GAAP measure, below. 
 

Share Structure and Insider Ownership

On September 27, 2026, approximately 13.5 million shares of Guardian's Class B common stock converted into Class A common stock, completing the two-year share conversion process that commenced with the Company's September 2024 corporate reorganization effected in connection with its initial public offering ("IPO").

Prior to the conversion, Guardian's founders, executive officers, and certain other employees entered into lock-up agreements covering approximately 29.9 million shares, representing approximately 80% of the Class A shares held by founders, executive officers, and other pre-IPO employee shareholders. These shares remain subject to lock-up restrictions through September 14, 2027, subject to limited exceptions.

The substantial continued ownership by Guardian's founders, management team, and employees reinforces their long-term alignment with Guardian's public shareholders.

Conference Call Details

Guardian will host a conference call to discuss these results today at 4:30 pm ET. The call can be accessed live by dialing +1 (833) 461-5787 for participants located in the United States and Canada, or +1 (585) 542-9983 for international participants, and referencing conference ID "969 326 559" A webcast replay will be available shortly after the call's completion at https://investors.guardianpharmacy.com

About Guardian Pharmacy Services

Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies. Through its locally--based business model, Guardian partners with long-term care facilities ("LTCFs") to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 63 licensed pharmacies, 57 of which are full-service, Guardian is dedicated to providing exceptional service to approximately 218,000 residents (as of September 30, 2026).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are all statements other than those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are not historical facts and are forward-looking. These statements are often, but not always, made through the use of words such as "aims," "anticipates," "believes," "continue," "estimates," "expects," "intends, " "may," "outlook," "plans," "projects," "seeks," "should," "will," "would," and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business and growth strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical and health care services in new and existing markets; our relationships with pharmaceutical wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; our ability to identify, complete and successfully integrate acquisitions; the impact of a national emergency, public health crisis, global pandemic or outbreak of infectious disease on our employees, business, supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by capping the prices for certain drugs and limiting pharmacy reimbursements; changes in, and our ability to comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure requirements, and our ability to raise additional capital, if needed; and the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense. We are subject to additional risks and uncertainties described in our periodic reports filed

with the Securities and Exchange Commission from time to time, including in the "Risk Factors" section contained in our most recent Annual Report on Form 10-K, which report is publicly available at www.sec.gov and via our website, investors.guardianpharmacy.com. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management's views as of the date hereof. Except to the extent required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.

Additional Information

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings. Copies of our reports are available on our website at no expense at investors.guardianpharmacy.com and through the SEC's website at www.sec.gov.

Use of Non-GAAP Financial Measures

To supplement the results presented in our consolidated financial statements in accordance with GAAP, we also present Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS, which are financial measures not based on any standardized methodology prescribed by GAAP.

We define Adjusted EBITDA as net income before interest expense (income), income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, certain legal and regulatory items, financing-related and other activities, and payor-reimbursement matters.

We define Adjusted Net Income as net income attributable to Guardian Pharmacy Services, Inc. before share-based compensation expense, certain legal and other regulatory items, financing-related and other activities, payor-reimbursement matters, amortization expense associated with acquisition-related intangible assets, and the income tax impact of the adjustments.

We define Adjusted EPS as Adjusted Net Income divided by the total weighted average of diluted shares for Class A common stock and Class B common stock.

Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not have a definition under GAAP, and our definition of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS may not be the same as, or comparable to, similarly titled measures used by other companies.

We use Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS to better understand and evaluate our core operating performance and trends. We believe that presenting Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance using the same metrics that management uses to evaluate our performance.

There are a number of limitations related to the use of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS rather than the most directly comparable GAAP financial measure, including:

   --  Adjusted EBITDA does not reflect interest and income tax payments that 
      represent a reduction in cash available to us; 
 
   --  Depreciation and amortization are non-cash charges and the assets being 
      depreciated may have to be replaced in the future, and Adjusted EBITDA 
      does not reflect cash capital expenditure requirements for such 
      replacements or for new capital expenditure requirements; 
 
   --  Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not reflect 
      changes in, or cash requirements for, our working capital needs; 
 
   --  Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS do not consider 
      the impact of share-based compensation; and 
 
   --  Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS exclude the 
      impact of certain legal and regulatory items, and payor-reimbursement 
      matters which can affect our current and future cash requirements. 

Because of these limitations, Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS alongside other financial measures, including net income, diluted EPS, and our other financial results presented in accordance with GAAP.

A reconciliation of Adjusted EBITDA to net income and of Adjusted Net Income to Net Income Attributable to Guardian Pharmacy Services, Inc., the most directly comparable GAAP financial measures, are set forth below.

Guardian has not provided a quantitative reconciliation of forecasted adjusted EBITDA to forecasted net income within this release because Guardian is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.

 
             GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES 
                   CONDENSED CONSOLIDATED BALANCE SHEETS 
                                (UNAUDITED) 
 
                                            December 31,     September 30, 
(In thousands, except share amounts)             2025             2026 
                                           ---------------  ---------------- 
Assets 
Current assets: 
   Cash and cash equivalents                $       65,619   $       119,655 
   Accounts receivable, net                        101,614           107,677 
   Inventories                                      43,359            57,051 
   Other current assets                             11,042            10,434 
                                               -----------      ------------ 
Total current assets                               221,634           294,817 
 
Property and equipment, net                         55,522            57,424 
Intangible assets, net                              18,475            20,842 
Goodwill                                            79,743            81,954 
Operating lease right-of-use assets                 34,649            32,774 
Deferred tax assets                                  2,199             2,618 
Other assets                                           436             1,347 
                                               -----------      ------------ 
Total assets                                $      412,658   $       491,776 
                                               ===========      ============ 
 
Liabilities and equity 
Current liabilities: 
   Accounts payable                         $      116,206   $       126,307 
   Accrued compensation                             15,048            19,874 
   Operating leases, current portion                 7,150             7,632 
   Other current liabilities                        22,299            25,276 
                                               -----------      ------------ 
Total current liabilities                          160,703           179,089 
 
Operating leases, net of current portion            29,992            27,962 
Other liabilities                                    4,039             5,005 
                                               -----------      ------------ 
Total liabilities                           $      194,734   $       212,056 
                                               -----------      ------------ 
 
Commitments and contingencies (see Note 
6) 
 
Equity: 
   Class A common stock - 700,000,000 
    shares authorized, par value $0.001; 
    36,253,744 and 63,320,300 shares 
    issued and outstanding as of December 
    31, 2025 and September 30, 2026, 
    respectively                                        36                63 
   Class B common stock - 100,000,000 
   shares authorized, par value $0.001; 
   27,066,890 and 22,004 shares issued 
   and outstanding as of December 31, 
   2025 and September 30, 2026, 
   respectively                                         27                -- 
   Additional paid-in capital                      139,353           146,982 
   Retained earnings                                66,343           120,190 
   Non-controlling interests                        12,165            12,485 
                                               -----------      ------------ 
Total equity                                       217,924           279,720 
                                               -----------      ------------ 
Total liabilities and equity                $      412,658   $       491,776 
                                               ===========      ============ 
 
 
         GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES 
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
                            (UNAUDITED) 
 
                   Three Months Ended        Nine Months Ended 
                       September 30,            September 30, 
                   --------------------  -------------------------- 
(In thousands, 
except share and 
per share 
amounts)             2025       2026        2025         2026 
                    -------    -------    ---------    --------- 
Revenues           $377,427   $371,070   $1,051,069   $1,059,433 
Cost of goods 
 sold               302,706    285,847      843,853      817,857 
                    -------    -------    ---------    --------- 
Gross profit         74,721     85,223      207,216      241,576 
 
Selling, general, 
 and 
 administrative 
 expenses            58,367     60,160      165,277      178,194 
                    -------    -------    ---------    --------- 
 
Operating income     16,354     25,063       41,939       63,382 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment